MoMed Biotech has garnered widespread attention since its inception due to its innovative research and cutting-edge technology. Recently, the company was interviewed by Zhejiang TV, and the program was officially broadcasted on the news channel's segment called "New Window of Science and Technology."

Artificial intelligence is a strategic technology leading the revolution in science and industrial transformation, and its application in the field of biomedicine is particularly significant. 

MOMED Biotech, as the world's first and only company driven by the mechanism research of drug targets, combines cutting-edge computational biology with artificial intelligence to innovate drug development. 

The company is committed to initiating a revolution in innovative drug development and aims to propel the transformation of China's pharmaceutical industry from "tracking and imitation" to "original innovation," injecting new energy into the field of innovative drug development.

MoMed Biotech has attracted considerable attention since its establishment for its innovative research approach and utilization of cutting-edge technology. Recently, the company was featured in an interview by Zhejiang TV, which was broadcasted on the news channel's segment called "New Window of Science and Technology."

During the interview, Professor Bai Chen, the founder and CEO, shared MoMed Biotech's founding concept of leveraging target protein mechanism research combined with advanced AI technology to empower innovative drug development. In 2013, Nobel Prize laureate in Chemistry, Professor Arieh Warshel, who is also Professor Bai Chen's mentor and collaborator, exclusively licensed MoMed Biotech with computational biology technology, leading to unprecedented breakthroughs in the company's core technology. 

MoMed Biotech integrates its unique computational biology theoretical system with artificial intelligence to conduct target protein mechanism research in the early stages of drug discovery for promising drug targets. This process aims to obtain crucial data to support the training of AI drug design models, resulting in the development of drug molecules with better efficacy and higher drug potential, all with independent intellectual property rights.

By utilizing its technology, MoMed Biotech offers end-to-end capabilities from target discovery to AI-assisted drug design and drug molecule optimization. These capabilities serve pharmaceutical companies, hospitals, or research institutions in the pharmaceutical industry, meeting their personalized drug development needs. The company provides unique professional technical services to the pharmaceutical industry for drug development, thereby enhancing drug development efficiency, establishing connections with the upstream and downstream of the industry chain, and empowering the industry as a whole.

MoMed Biotech has established a professional R&D team with an international perspective, comprised of renowned professor-level researchers from prestigious universities such as Peking University, Shanghai Jiao Tong University, Zhejiang University, University of Macau, and China Pharmaceutical University. The company has constructed a specialized R&D team equipped with advanced computational biology and artificial intelligence technology, dedicated to advancing innovation in drug development.

Currently, MoMed Biotech has multiple self-developed drug pipelines covering significant drug targets such as enzymes, ion channels, and G protein-coupled receptors, which address major diseases affecting modern human health such as cancer, cardiovascular disease, and diabetes.

We firmly believe that through continuous effort and innovation, MoMed Biotech will strive to become a global technology enterprise leading the integration of biomedicine and artificial intelligence, making significant contributions to the cause of human health!